Is Enlivex Therapeutics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: ENLV) stock is to Strong Buy ENLV stock.
Out of 2 analysts, 1 (50%) are recommending ENLV as a Strong Buy, 1 (50%) are recommending ENLV as a Buy, 0 (0%) are recommending ENLV as a Hold, 0 (0%) are recommending ENLV as a Sell, and 0 (0%) are recommending ENLV as a Strong Sell.
What is ENLV's earnings growth forecast for 2025-2025?
(NASDAQ: ENLV) Enlivex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.93%.
Enlivex Therapeutics's earnings in 2025 is -$18,933,000.
In 2025, ENLV is forecast to generate -$12,321,154 in earnings, with the lowest earnings forecast at -$12,321,154 and the highest earnings forecast at -$12,321,154.
What is ENLV's forecast return on equity (ROE) for 2025-2026?
(NASDAQ: ENLV) forecast ROE is N/A, which is considered weak.
What is ENLV's Price Target?
According to 2 Wall Street analysts that have issued a 1 year ENLV price target, the average ENLV price target is $10.00, with the highest ENLV stock price forecast at $13.00 and the lowest ENLV stock price forecast at $7.00.
On average, Wall Street analysts predict that Enlivex Therapeutics's share price could reach $10.00 by Mar 24, 2026. The average Enlivex Therapeutics stock price prediction forecasts a potential upside of 890.1% from the current ENLV share price of $1.01.
What is ENLV's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ENLV) Enlivex Therapeutics's current Earnings Per Share (EPS) is -$0.98. In 2025, ENLV's EPS is forecast to hit -$0.59 (min: -$0.59, max: -$0.59).
What is ENLV's forecast return on assets (ROA) for 2025-2026?
(NASDAQ: ENLV) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 3,925.79%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.